TableĀ 1

Baseline characteristics according to indication for warfarin

Number of treatment periods on warfarin
AllAortic valveMitral valve*
n=4687n=3656n=1031
Mean age (SD)63.26 (13.43)62.91 (12.94)64.51 (13.98)
Female sex n (%)1442 (30.8)1022 (28.0)420 (40.7)
Mean interpolated INR (SD)2.65 (0.43)2.63 (0.43)2.73 (0.45)
TTR (SD)72.5 (19.6)74.2 (18.5)66.7 (23.6)
Target INR 2.5 n (%)3076 (65.6)2581 (70.8)495 (48.1)
Target INR 3.0 n (%)400 (8.5)158 (4.3)242 (23.5)
Treatment periods in patients with at least one diagnosis in the National Patient Register before warfarin start
n=4299n=3332n=967
Diabetes n (%)468 (10.9)348 (10.4)120 (12.4)
Hypertension n (%)1242 (28.9)980 (29.4)262 (27.1)
Previous stroke/TIA n (%)511 (11.9)377 (11.3)134 (13.9)
Liver disease n (%)26 (0.6)18 (0.5)8 (0.8)
Kidney disease n (%)136 (3.2)92 (2.8)44 (4.6)
COPD n (%)154 (3.6)104 (3.1)50 (5.2)
Atrial fibrillation n (%)1483 (34.5)936 (28.1)547 (56.6)
Heart failure n (%)1160 (27.0)730 (21.9)430 (44.5)
Previous major bleeding n (%)288 (6.7)207 (6.2)81 (8.4)
  • Mean age and gender are presented for all patients, concomitant diseases only for those patients who had at least one diagnosis in the patient register before start of warfarin. Presented as number and proportion of patients, n (%). A patient could have one or several indications for warfarin treatment.

  • *Includes patients with both aortic and mitral prostheses.

  • COPD, chronic obstrucitve pulmonary disease; INR, international normalised ratio; TTR, time in therapeutic range.